Division of Radiology and Nuclear Medicine, Department of Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
J Alzheimers Dis. 2022;85(1):197-205. doi: 10.3233/JAD-215046.
Patients with Alzheimer's disease (AD) show heterogeneity in clinical progression rate, and we have limited tools to predict prognosis. Amyloid burden from 18F-Flutemetamol positron emission tomography (PET), as measured by standardized uptake value ratios (SUVR), might provide prognostic information.
We investigate whether 18F-Flutemetamol PET composite or regional SUVRs are associated with trajectories of clinical progression.
This observational longitudinal study included 94 patients with clinical AD. PET images were semi-quantified with normalization to pons. Group-based trajectory modeling was applied to identify trajectory groups according to change in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) over time. Multinomial logistic regression models assessed the association of SUVRs with trajectory group membership.
Three trajectory groups were identified. In the regression models, neither composite nor regional SUVRs were associated with trajectory group membership.
There were no associations between CDR progression and 18F-Flutemetamol PET-derived composite SUVRs or regional SUVRs in clinical AD.
阿尔茨海默病（AD）患者的临床进展速度存在异质性，我们预测预后的手段有限。18F-Flutemetamol 正电子发射断层扫描（PET）的淀粉样蛋白负荷，以标准化摄取值比（SUVr）衡量，可能提供预后信息。
我们研究 18F-Flutemetamol PET 综合或区域 SUVr 是否与临床进展轨迹相关。
本观察性纵向研究纳入了 94 例临床 AD 患者。采用基于群组的轨迹建模，根据临床痴呆评定量表总和评分（CDR-SB）随时间的变化来识别轨迹组。多项逻辑回归模型评估了 SUVr 与轨迹组归属的相关性。
确定了三个轨迹组。在回归模型中，综合 SUVr 和区域 SUVr 均与轨迹组归属无关。
在临床 AD 中，CDR 进展与 18F-Flutemetamol PET 衍生的综合 SUVr 或区域 SUVr 之间无关联。
